Cargando…
Standardising Care and Treatment of Transthyretin Amyloid Cardiomyopathy
Transthyretin cardiac amyloidosis (ATTR-CA) has been traditionally considered a rare and inexorably fatal condition. ATTR-CA now is an increasingly recognised cause of heart failure and mortality worldwide with effective pharmacological treatments. Advances in non-invasive diagnosis, coupled with th...
Autores principales: | Fontana, Marianna, Porcari, Aldostefano, Hawkins, Philip N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ubiquity Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10668877/ https://www.ncbi.nlm.nih.gov/pubmed/38028963 http://dx.doi.org/10.5334/gh.1275 |
Ejemplares similares
-
Transthyretin amyloid cardiomyopathy: An uncharted territory awaiting discovery
por: Porcari, Aldostefano, et al.
Publicado: (2020) -
Transthyretin cardiac amyloidosis
por: Porcari, Aldostefano, et al.
Publicado: (2022) -
Sex differences among patients with transthyretin amyloid cardiomyopathy – from diagnosis to prognosis
por: Patel, Rishi K., et al.
Publicado: (2022) -
Cardiac transplantation in transthyretin amyloid cardiomyopathy: Outcomes from three decades of tertiary center experience
por: Razvi, Yousuf, et al.
Publicado: (2023) -
Systemic embolism in amyloid transthyretin cardiomyopathy
por: Vilches, Silvia, et al.
Publicado: (2022)